Christine Siu
About Christine Siu
Christine Siu, age 48 as of March 31, 2025, is an independent director of Monte Rosa Therapeutics (GLUE) and serves as Chair of the Audit Committee, designated by the Board as its “audit committee financial expert.” She has been on GLUE’s Board since December 2020, with prior senior operating and finance roles across biopharma and investing. She holds an MBA from Harvard Business School and a BS (with distinction) in cellular molecular biology and economics from the University of Michigan .
Past Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Pancreative Sciences (GondolaBio portfolio company) | Chief Executive Officer | Feb 2025–present | Biopharma startup leadership |
| ML Bio Solutions (BridgeBio affiliate) | Chief Executive Officer | Jan 2022–present | BridgeBio affiliate CEO role |
| BridgeBio Pharma | Chief Operating Officer in Residence | Jan 2020–Jan 2022 | Operating leader across portfolio |
| Eidos Therapeutics | Chief Financial Officer | Dec 2017–Dec 2019 | Public biopharma CFO |
| Eidos Therapeutics | Chief Operating Officer | Apr 2016–Dec 2017 | Scaling operations |
| The Bluefield Project to Cure FTD | Chief Business Officer | 2014–2017 | Non-profit neurodegeneration program |
| Global Blood Therapeutics | Sr. Director, Corporate Development | 2012–2014 | BD at commercial-stage biopharma |
| Third Rock, Warburg Pincus, Thomas McNerney | Investor (Life Sciences) | Prior to 2012 | VC/PE investing background |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Bright Peak Therapeutics (private) | Director | Jun 2021–present | Privately held biotech; committee details not disclosed |
Board Governance
- Committee leadership and membership: Audit Committee Chair; members include Siu, Andrew Schiff, and Chandra Leo; Siu designated “audit committee financial expert” .
- Independence: The Board determined all directors other than the CEO are independent under Nasdaq/SEC rules; Siu is independent .
- Attendance and engagement: Board met 15 times in 2024; all directors attended at least 75% of Board and committee meetings; Audit Committee met 4 times in 2024 .
- Risk oversight: Audit Committee responsibilities include financial reporting, internal controls, related-party reviews, and cybersecurity risk oversight; annual Audit Committee report signed by Siu as Chair .
Fixed Compensation
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Cash fees (retainers/committee) ($) | 52,500 | 55,000 |
| Total cash + equity ($) | 150,884 | 124,016 |
Non-Employee Director Compensation Policy (in effect; amended/restated June 2024):
- Annual Board retainer: $40,000
- Non-executive Chair premium: $30,000
- Audit or Compensation Committee member: $7,500; Chair: $15,000
- Nominating & Corporate Governance Committee member: $4,000; Chair: $8,000
- Equity: Continuing directors granted options to purchase 22,100 shares on the date of the 2024 annual meeting; vests in full by the earlier of first anniversary or next annual meeting; 100% acceleration upon change in control
Performance Compensation
| Year | Option Awards Fair Value ($) | Continuing Director Annual Option Grant Shares (Policy) | Vesting (Policy) | Change-in-control (Policy) |
|---|---|---|---|---|
| 2023 | 98,384 | 20,500 | Full by earlier of 1st anniversary or next annual meeting | 100% acceleration |
| 2024 | 69,016 | 22,100 | Full by earlier of 1st anniversary or next annual meeting | 100% acceleration |
Notes:
- Awards values reported per ASC 718 and may not equal realized value .
- No RSUs/PSUs disclosed for directors as of FY 2024; options are the primary equity vehicle .
Other Directorships & Interlocks
| Company | Role | Public/Private | Potential Interlock/Conflict Considerations |
|---|---|---|---|
| Bright Peak Therapeutics | Director | Private | No GLUE-related transactions disclosed; Audit Committee reviews related persons |
| ML Bio Solutions | CEO | Private/affiliate of BridgeBio | No GLUE-related transactions disclosed |
| Pancreative Sciences | CEO | Private | No GLUE-related transactions disclosed |
- Related-party transactions review: GLUE reports no director-related transactions meeting Item 404 thresholds since Jan 1, 2023, other than offerings involving >5% holders (Baker Bros., T. Rowe, FMR, Vanguard) unrelated to Siu personally .
Expertise & Qualifications
- Designated Audit Committee Financial Expert; deep finance/audit literacy .
- Senior finance and operating roles at Eidos Therapeutics; investor background at top-tier VC/PE firms .
- Academic credentials: MBA (Harvard), BS with distinction (University of Michigan) .
Equity Ownership
| Metric | Value | As-of |
|---|---|---|
| Beneficial ownership (options exercisable within 60 days) | 118,563 shares; <1% of outstanding | Mar 31, 2025 |
| Aggregate shares subject to stock options (outstanding) | 140,663 shares | Dec 31, 2024 |
| Hedging/pledging | Company policy prohibits hedging, short sales, and pledging; no waivers noted |
Policy backdrop:
- Insider trading policy prohibits derivatives/hedging and pledging, with Audit Committee approval required for any waiver; none made to date .
Governance Assessment
- Board effectiveness: Siu’s chairmanship of the Audit Committee and designation as financial expert strengthen oversight of financial reporting, internal controls, and cybersecurity risk—positive for investor confidence .
- Independence and engagement: Independent under Nasdaq; Audit Committee met 4 times; Board attendance at least 75% across directors—adequate engagement .
- Alignment and incentives: Director cash fees align with policy; equity awards in options that vest on a near-term schedule provide some alignment but result in modest beneficial ownership (<1%), typical for emerging growth biotech boards .
- Conflicts/related-party exposure: Despite external CEO roles (ML Bio Solutions, Pancreative Sciences), no related-party transactions involving Siu disclosed; Audit Committee oversees related-person reviews—no evident red flags .
- Compensation structure signals: Year-over-year reduction in option fair value (2023→2024) and stable cash fees (aligned with audit chair premium) suggest no pay inflation or anomalous guarantees; director equity features standard CIC acceleration .
Red flags: None identified in disclosures—no pledging/hedging, no director-related party transactions, independent status maintained, attendance thresholds met .